Sarepta Investing in CRISPR Technology to Develop DMD Drugs – Rare Disease Report (blog)
Rare Disease Report (blog) |
Sarepta Investing in CRISPR Technology to Develop DMD Drugs
Rare Disease Report (blog) “Although early, CRISPR technology represents hope for a large percentage of individuals with DMD. Excising certain exons has the potential to correct a majority of DMD mutations. Toward that goal, we've shown in mouse models that we can excise exons … Sarepta Therapeutics, Inc. (SRPT) registers a price change of 2.84% while CRISPR Therapeutics AG (CRSP) finishes … Sarepta and Duke University Collaborating on Gene Editing as a Treatment for Duchenne MD |
